Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 4Ovarian Neoplasms 2Colorectal Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Somatostatinoma 1Small Cell Lung Carcinoma 1Neoplasms 1Metastatic Pancreatic Adenocarcinoma 1Metastatic Adenocarcinoma of the Pancreas 1Locally Advanced Pancreatic Carcinoma(LAPC) 1Head and Neck Neoplasms 1Glioblastoma 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Biliary Tract Neoplasms 1Advanced Pancreatic Cancer 1

Interventions

Temozolomide 4Capecitabine 4Bevacizumab 3Leucovorin 2Fluorouracil 2Everolimus 2temsirolimus 1sapanisertib 1regorafenib 1pentetreotide 1pazopanib 1motesanib diphosphate 1irinotecan sucrosofate 1gallium Ga 68 dotatate 1dehydroftorafur 1batifiban 1aflibercept 1Sunitinib 1Sorafenib 1Sirolimus 1Panobinostat 1Oxaliplatin 1Octreotide 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Fentanyl 1Etoposide 1Doxorubicin 1Disulfides 1Cytidine Triphosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Somatostatinoma × irinotecan sucrosofate × Clear all
NCT03736720 2025-01-30

Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin

Roswell Park Cancer Institute

Phase 2 Terminated
11 enrolled 17 charts

Somatostatinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡